The Department of Healthcare and Family Services issued a Provider Notice RE: Rybelsus Tablets to Ozempic Tablets. This change will apply to both the fee-for-service (FFS) program and Managed Care Organizations (MCOs) plans. There are no changes to Ozempic injections.
Novo Nordisk informed the Department of Healthcare and Family Services (HFS) that it will discontinue all strengths of Rybelsus tablets, requiring patients to be transitioned to Ozempic tablets. Beginning in May 2026, shipments of Rybelsus tablets to wholesalers will cease, with existing inventory expected to become limited starting in July 2026.
Please see notice for details. Questions regarding this notice may be directed to the Bureau of Professional and Ancillary Services at 877-782-5565 or the applicable MCO.
For more information, contact NACDS’ Leigh Knotts at 803-243-7207.